ClinicalTrials.gg
WithdrawnNCT07223294Updated May 12, 2026

Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma

A Phase 3 interventional study of Fluticasone furoate and vilanterol inhalation powder and Breo Ellipta in Respiratory, sponsored by Sandoz. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
In response to evolving regulations, product specific guidance by Health Authorities globally, Sandoz plans to streamline its clinical development programs and has therefore strategically decided to discontinue the SAN 1138 clinical study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a randomized, multi-center, multiple-dose, double-blind, placebo-controlled, Parallel group design, clinical endpoint bioequivalence study in adult participants with asthma.

The study design includes up to a 2-week Screening period, at least a 2-week Run-in period, a 4-week Treatment period, and a safety follow up call one week later.

Visit 1: Screening Visit 2: Run-in period: All eligible participants will enter a 2-week Run-in period in which training will be provided to the participants on the use of inhalers and participant diary.

Visit 3: Day 1: Randomization to one of the 3 treatment groups to receive one inhalation of the study medication quaque die (QD), in the morning, for 28 ± 2 days.

Visit 4: Day 28: EOT

Participants will be contacted one week after their last site visit for Safety follow-up via phone call (end of study). Participants will be instructed to refrain from taking their current inhaled asthma medications from the start of the Run-in period until the end of treatment (EOT) visit. They will be provided with a salbutamol/albuterol inhaler (rescue medication) for use on an as-needed basis during the entire study duration until the EOT visit.

02

Conditions studied

  • Respiratory
03

In context

Lead sponsor

Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

First submitted after Sandoz left Novartis.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed (as described in the protocol), which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol.
  • Participants must be 18 to 75 years old (inclusive) at Screening (signing the ICF).
  • Diagnosis of asthma, as defined by the National Asthma Education and Prevention Program, at least 12 weeks prior to Screening.
  • Participants who are stable on their chronic asthma treatment regimen for at least 4 weeks prior to Screening.
  • Pre-bronchodilator of >40% and \<85% of predicted value, at Screening.
  • Participants with FEV1 reversibility of ≥12% and ≥200 mL within 30 minutes following 360 mcg of albuterol inhalation (via pressurized metered dose inhaler pressurized metered-dose inhaler [pMDI]) or equivalent at Screening.
  • This what you mean: Participants who are currently non-smoking and have not used tobacco smoking or smoked marijuana products, within the past year.
  • Participants who are able to replace their current regularly scheduled short-acting β2-agonists (SABAs) with a salbutamol/albuterol inhaler for use only on an 'as-needed' basis for the duration of the study.
  • Participants must be able to discontinue their asthma medications during the Run-in period, and for the remainder of the study.
  • Participants who can demonstrate the correct use of inhaler device (during the Run-in period and at Randomization visit).
  • Participants are eligible to participate in this study if they are:
  • Of non-
  • Of childbearing potential, and if they agree to use a highly effective form of consistently during the study, starting at Screening and until the end of study (EOS). These participants must have a negative pregnancy test at Screening and Randomization visit.
  • Participants who produce viable sperm and have a partner of childbearing potential, and if they agree to use an adequate method of contraception consistently during the study, starting at Screening and until the EOS and also refrain from donating sperm during this period. Participants with a partner or partners who is (are) not of childbearing potential are exempt from these requirements.

Exclusion criteria

Exclusion Criteria:

  • Participants who have life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma-related syncopal episodes(s), or hospitalizations within one year prior to Screening or during the Run-in period.
  • Participants with significant chronic respiratory disease (, interstitial lung disease, etc) other than asthma which in the opinion of the Investigator may interfere with the study evaluation or optimal participation in the study.
  • Participants with evidence or history of disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, cardiac dysrhythmia, significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that in the opinion of the Investigator, would put them at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
  • Participants with asthma exacerbations (ie, acute or sub-acute worsening in symptoms and lung function from the participant's usual status) within 6 weeks prior to Screening or during the Run-in period.
  • Participants with evidence or history of tuberculosis (additionally confirmed with a chest X-ray done within 6 months prior to Screening for countries with high tuberculosis risk).
  • Participants with uncontrolled allergic rhinitis within 15 days prior to Screening.
  • Viral, bacterial, fungal, or parasitic, acute upper or lower respiratory tract infection (including Coronavirus Disease (COVID-19)), or sinus, or middle ear infection within 4 weeks prior to Screening, during the Run-in period, or at the Randomization visit. Note: Rescreening of participants with acute respiratory conditions during the Screening and Run-in period may be allowed in consultation with Medical Monitor (Section 5.4).
  • Participants with a history of , , or 1 and 2.
  • Participants with clinically significant screening laboratory and (ECG) parameters as per Investigator's assessment.
  • Participants receiving systemic, oral, parenteral or depot , or anti-immunoglobulin E (IgE) therapy within 12 weeks prior to Screening spirometry or unable to stop receiving these medications during the study.
  • Participants receiving β2-blockers, anti-arrhythmics, anti-depressants, monoamine oxidase inhibitors, cytochrome P450 3 subfamily A member 4 (3A4) inhibitors, or diuretics within 4 weeks prior to the Screening spirometry or unable to stop receiving these medications during the study.
  • Participants receiving monoclonal antibodies that may affect the course of asthma within 180 days prior to the Screening spirometry or unable to stop receiving these medications during the study.
  • Participants receiving within two days prior to Screening.
  • Participants who received an drug within 28 days or 5 half-lives (whichever is longer) prior to Screening.
  • to any sympathomimetic drug (eg, albuterol, vilanterol) or to any inhaled, intranasal, or systemic corticosteroid therapy, or to milk proteins, or to in the dry powder inhaler.
  • Participants with significant alcohol or controlled substance abuse in the past 6 months, per the judgment of the Investigator.
  • Participants with any factors (eg, infirmity, disability, or geographic location) that the Investigator feel would likely limit the participants' compliance with the study protocol or scheduled clinic visits.
  • Participants who cannot communicate reliably or who are unlikely to co-operate with the requirements of the study, in the opinion of the Investigator.

Participants who are pregnant, breastfeeding, or planning to become pregnant during the study.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Fluticasone furoate and vilanterol inhalation powder

    Fluticasone furoate and Vilanterol inhalation powder 100 mcg/25 mcg QD for 4 weeks

    Combination Product: Fluticasone furoate and vilanterol inhalation powder

  • Active comparator
    Breo Ellipta

    Fluticasone furoate and Vilanterol inhalation powder 100 mcg/25 mcg QD for 4 weeks

    Combination Product: Breo Ellipta

  • Placebo comparator
    Placebo

    Placebo QD for 4 weeks

    Combination Product: Placebo

Interventions

  • Combination productFluticasone furoate and vilanterol inhalation powder

    Fluticasone furoate and vilanterol inhalation powder 100 mcg/25 mcg

  • Combination productBreo Ellipta

    Fluticasone furoate and Vilanterol inhalation powder) 100 mcg/25 mcg

  • Combination productPlacebo

    Inhalation powder with lactose

06

What researchers measure

Primary outcomes

  1. Demonstrate the therapeutic equivalence of test and reference product

    Forced Expiratory Volume in 1 Second (FEV1) Are Under Curve (AUC 0-24) on Day 1

    Time frame: Day 1 (0-24Hrs)

  2. Demonstrate the therapeutic equivalence of test and reference product

    trough Forced Expiratory Volume in 1 Second (FEV1 on Day 28)

    Time frame: Day 28 of treatment

  3. Demonstrate the superiority of test and reference product over placebo

    Forced Expiratory Volume in 1 Second (FEV1) Are Under Curve (AUC 0-24) on Day 1

    Time frame: Day 1 (0-24 hours (Hrs)

  4. Demonstrate the superiority of test and reference product over placebo

    trough Forced Expiratory Volume in 1 Second (FEV1 on Day 28)

    Time frame: Day 28 of treatment

Secondary outcomes

  1. To compare the number and type of Adverse Events of Test, Reference and Placebo

    Number of Adverse Events, Serious Adverse Events, Treatment-Emergent Adverse Events (TEAE)

    Time frame: Screening to week 5 (End of study)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2025
First posted
Oct 31, 2025
StartEst.
Apr 21, 2026
Primary completionActual
Apr 21, 2026
CompletionActual
Apr 21, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07223294
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Apr 21, 2026 (estimated)
Primary completion
Apr 21, 2026
Completion
Apr 21, 2026
Last update
May 12, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion